Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06340854 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
A Phase 3 study of Diabetes Type 2, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 429
- Enrollment target
- 20
- Study locations
NCT06340854: Completed Phase 3 study of Diabetes Type 2, sponsored by Novo Nordisk A/S.
NCT06340854 is a Phase 3 study of Diabetes Type 2 that has completed, run by Novo Nordisk A/S. The registered enrollment target is 429 participants, below the 650-participant average among 24 other Diabetes Type 2 trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06340854, a Phase 3 study of Diabetes Type 2, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 429 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec once a week, or one injection of insulin glargine once a day, depending on the treatment group participants are assigned into. Participants will use a pen with a small needle to inject the medicine under participants skin into participants thigh, upper arm or stomach.The study will last for about 9 months, but participants will only be taking the study medicine for 6 months.
Primary Outcome
Change in HbA1c from week 0 to week 26 in percentage point is presented.
Conditions Studied
Interventions
- DRUG Insulin icodec
- DRUG Insulin glargine
Study Locations (20)
Texas
- Amarillo Medical Specialists - Amarillo
- Velocity Clinical Res-Dallas - Dallas
- Victorium Clinical Research - Houston
- PlanIt Research, PLLC - Houston
California
- Advanced Investigative Medicine, Inc. - Hawthorne
- Scripps Whittier Diabetes Inst - La Jolla
- Clinical Trials Research - Lincoln
Florida
- Northeast Research Institute of Florida - Fleming Island
- South Broward Research LLC - Miramar
North Carolina
- PharmQuest Life Sciences LLC - Greensboro
- Accellacare Wilmington - Wilmington
Georgia
- Endo Res Solutions Inc - Roswell
Kansas
- Cotton-Oneill Diabetes and End - Topeka
Minnesota
- International Diabetes Center - Minneapolis
Missouri
- Jefferson City Medical Group, PC - Jefferson City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 429 participants |
| Start Date | 2024-04-19 |
| Est. Completion | 2025-06-13 |
| Phase | Phase 3 |
What the finished NCT06340854 record still lists
NCT06340854 is an interventional study that assigns participants to a tested intervention. The registered 429 participants enrollment target is mid-sized for trials with a published cap, below the 650-participant average among 24 other Diabetes Type 2 trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Diabetes Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Insulin icodec is the first listed.
NCT06340854 names 20 study sites across 13 states, led by Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06340854 about?
NCT06340854 is a clinical study titled "A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes". This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is de...
What is the current status of trial NCT06340854?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 429 participants. The study started on 2024-04-19. Estimated completion is 2025-06-13.
What conditions does trial NCT06340854 study?
This clinical trial studies the following conditions: Diabetes Type 2.
What interventions are being tested in trial NCT06340854?
The interventions under investigation include: Insulin icodec (DRUG), Insulin glargine (DRUG).
Who is sponsoring clinical trial NCT06340854?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06340854 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06340854's enrollment target sits among peer trials
429 6th of 24 higher than 19 of 24 other Diabetes Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
COMPLETED · Phase 3
-
Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix
COMPLETED · Phase 3
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
RECRUITING · NA
-
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
RECRUITING · NA
-
Medically Intensive Nutrition Therapy Program for Obesity and Diabetes in a Low-income Population
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05932862 · 429 participants · Phase 1
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI